

Jessica Li

9609 Medical Center Dr Rm 5W212
Rockville, MD 20850

(240) 276-5308 (Office)
jessica.li3@nih.gov

Education

The George Washington University (GWU)
Master of Public Health in Biostatistics

Washington, D.C.
May 2018

University of Maryland, College Park
Bachelor of Science in Mathematics

College Park, MD
Dec 2014

Work Experience

National Institutes of Health

Biometric Research Program, National Cancer Institute
Mathematical Statistician

Rockville, MD
Sep 2021 - Present

Johns Hopkins University

Lupus Center, Department of Medicine - Rheumatology
Senior Research Data Analyst

Baltimore, MD
Mar 2018 - Aug 2021

DC Department of Health/GWU School of Public Health

HIV/AIDS, Hepatitis, STD and TB Administration
Graduate Research Assistant

Washington, D.C.
May 2016 - Feb 2018

Publications

1. Best AF, Bowman M, Li J, Mishkin GE, Denicoff A, Shekfeh M, Rubinstein L, Warner JL, Rini B, Korde LA. COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS). *J Natl Cancer Inst.* 2023 May 8;115(5):597-600. doi: 10.1093/jnci/djad015. Erratum in: *J Natl Cancer Inst.* 2023 May 13;: PMID: 36702472; PMCID: PMC10165483.
2. Das S, Li JJ, Allston A, Kharfen M. Planning area-specific prevention and intervention programs for HIV using spatial regression analysis. *Public Health.* 2019 Apr;169:41-49. doi: 10.1016/j.puhe.2019.01.009. Epub 2019 Feb 25. PMID: 30818103.
3. Doshi RK, Li J, Dorsey K, Allston A, Kharfen M. Earlier diagnoses and faster treatment of HIV in the District of Columbia: HIV surveillance analysis, 2006-2016. *AIDS Care.* 2019 Dec;31(12):1476-1483. doi: 10.1080/09540121.2019.1595516. Epub 2019 Mar 22. PMID: 30897926.
4. Petri M, Elkhalfi M, Li J, Magder LS, Goldman DW. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. *Arthritis Rheumatol.* 2020 Mar;72(3):448-453. doi: 10.1002/art.41121. Epub 2020 Jan 7. PMID: 31532077; PMCID: PMC7050401.
5. Petri M, Konig MF, Li J, Goldman DW. Higher Hydroxychloroquine Blood Levels Are Associated with Reduced Thrombosis Risk in Systemic Lupus Erythematosus. *Arthritis Rheumatol.* 2021 Jan 5. doi: 10.1002/art.41621. Epub ahead of print. PMID: 33403833.
6. Kallas R, Li J, Petri M. Predictors of osteonecrosis in systemic lupus erythematosus: A prospective cohort study. *Arthritis Care Res (Hoboken).* 2020 Dec 20. doi: 10.1002/acr.24541. Epub ahead of print. PMID: 33342072.
7. Kallas R, Li J, Petri M. Association of African-American ethnicity and smoking status with total and individual damage index in systemic lupus erythematosus. *Clin Rheumatol.* 2020 Feb;39(2):365-373. doi: 10.1007/s10067-019-04800-1. Epub 2019 Nov 8. PMID: 31705325; PMCID: PMC7340111.
8. Mizus M, Li J, Goldman D, Petri MA. Autoantibody clustering of lupus-associated pulmonary hypertension. *Lupus Sci Med.* 2019 Dec 2;6(1):e000356. doi: 10.1136/lupus-2019-000356. PMID: 31908817; PMCID: PMC6928462.

9. Stojan G, **Li J**, Budoff M, Arbab-Zadeh A, Petri MA. High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index. *Lupus Sci Med*. 2020 Jul;7(1):e000409. doi: 10.1136/lupus-2020-000409. PMID: 32723810; PMCID: PMC7388871.
10. Stojan G, **Li J**, Wittmaack A, Petri M. Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage. *Arthritis Care Res (Hoboken)*. 2020 Aug 2;10.1002/acr.24395. doi: 10.1002/acr.24395. Epub ahead of print. PMID: 32741060; PMCID: PMC7855238.
11. Stojan G, **Li J**, Liu T, Kane MA, Petri MA. Intracellular homocysteine metabolites in SLE: plasma S-adenosylhomocysteine correlates with coronary plaque burden. *Lupus Sci Med*. 2021 Jan;8(1):e000453. doi: 10.1136/lupus-2020-000453. PMID: 33479047; PMCID: PMC7825256.
12. Demir S, **Li J**, Magder LS, Petri M. Antiphospholipid Patterns Predict Risk of Thrombosis in Systemic Lupus Erythematosus. *Rheumatology (Oxford)*. 2020 Dec 17;keaa857. doi: 10.1093/rheumatology/keaa857. Epub ahead of print. PMID: 33331921.
13. Babaoğlu H, **Li J**, Goldman D, Magder LS, Petri M. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. *Arthritis Care Res (Hoboken)*. 2020 Feb;72(2):225-232. doi: 10.1002/acr.24063. Epub 2020 Jan 9. PMID: 31507071; PMCID: PMC6992499.
14. Babaoğlu H, **Li J**, Goldman D, Magder LS, Petri M. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50). *Lupus*. 2019 Dec;28(14):1648-1655. doi: 10.1177/0961203319886028. Epub 2019 Nov 6. PMID: 31694446; PMCID: PMC6872940.
15. Goules A, **Li J**, Antiochos B, Goldman DW, Rosen A, Petri M, Casciola-Rosen L. Anti-retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis. *ACR Open Rheumatol*. 2019 Jun 6;1(5):287-291. doi: 10.1002/acr2.1036. PMID: 31777805; PMCID: PMC6857985.
16. Hair P, Goldman DW, **Li J**, Petri M, Krishna N, Cunnion K. Classical complement activation on human erythrocytes in subjects with systemic lupus erythematosus and a history of autoimmune hemolytic anemia. *Lupus*. 2020 Sep;29(10):1179-1188. doi: 10.1177/0961203320936347. Epub 2020 Jul 12. PMID: 32659155.
17. Shah AA, Igusa T, Goldman D, **Li J**, Casciola-Rosen L, Rosen A, Petri M. Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. *Arthritis Res Ther*. 2021 Feb 25;23(1):64. doi: 10.1186/s13075-021-02449-3. PMID: 33632283; PMCID: PMC7905617.
18. Antiochos B, Trejo-Zambrano D, Fenaroli P, Rosenberg A, Baer A, Garg A, Sohn J, **Li J**, Petri M, Goldman DW, Mecoli C, Casciola-Rosen L, Rosen A. The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular traps. *Elife*. 2022 May 24;11:e72103. doi: 10.7554/eLife.72103. PMID: 35608258; PMCID: PMC9129876.
19. Deonaraine KK, Carlucci PM, Fava A, **Li J**, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH; Accelerating Medicines Partnership RA/SLE network, Petri MA, Buyon JP. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. *Lupus Sci Med*. 2021 Aug;8(1):e000522. doi: 10.1136/lupus-2021-000522. PMID: 34389634; PMCID: PMC8354250.
20. Gomez-Bañuelos E, Wahadat MJ, **Li J**, Paz M, Antiochos B, Celia AI, Andrade V, Ferris DP, Goldman DW, Darrach E, Petri M, Andrade F. Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus. *JCI Insight*. 2022 Oct 10;7(19):e163795. doi: 10.1172/jci.insight.163795. PMID: 36040804; PMCID: PMC9675474.
21. Kallas R, **Li J**, Goldman DW, Magder LS, Petri M. Trajectory of Damage Accrual in Systemic Lupus Erythematosus Based on Ethnicity and Socioeconomic Factors. *J Rheumatol*. 2022 Nov;49(11):1229-1235. doi: 10.3899/jrheum.211135. Epub 2022 Aug 1. PMID: 35914791.

22. Fava A, Fenaroli P, Rosenberg A, Bagnasco S, **Li J**, Monroy-Trujillo J, Fine D, Atta MG, Petri M. History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis. *Rheumatology (Oxford)*. 2022 May 30;61(6):2483-2493. doi: 10.1093/rheumatology/keab775. PMID: 34664621; PMCID: PMC9308381.
23. Connolly CM, **Li J**, Goldman D, Fava A, Magder L, Petri M. Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function. *Lupus*. 2022 Oct;31(11):1367-1372. doi: 10.1177/09612033221111958. Epub 2022 Jul 1. PMID: 35775881; PMCID: PMC9547824.
24. Antiochos B, Paz M, **Li J**, Goldman DW, Petri M, Darrah E, Cashman K, Sanz I, Burns KH, Ardeljan D, Andrade F, Rosen A. Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activity. *Clin Exp Rheumatol*. 2022 Sep;40(9):1636-1641. doi: 10.55563/clinexprheumatol/bfz387. Epub 2021 Oct 13. PMID: 34665712.
25. Carlucci PM, **Li J**, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH; Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon JP, Petri M. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. *Rheumatology (Oxford)*. 2022 Nov 2;61(11):4335-4343. doi: 10.1093/rheumatology/keac067. PMID: 35212719; PMCID: PMC9629353.